In an intriguing new book, In 100 Years: Leading Economists Predict the Future, climate change plays a prominent role in most forecasts
Without access to the Malaysia Airlines flight’s data and voice recorders, investigators have little chance of learning what went wrong
Party leaders haven't abandoned him. He may actually be in a stronger position than he was a year ago
While Apple agreed to pay $32.5 million in refunds and build barriers to keep kids from spending on in-app purchases, Google says little
Public opinion polls in India are often rigged in exchange for envelopes of cash
How a dedicated and determined group of engineers—many of them Google or Y Combinator alums—worked to save Obamacare
Microsoft's Xbox One sales need a big boost from exclusive game Titanfall
European MBA programs compete with top-tier U.S. schools for the best students at home and abroad
States are investing in big data technologies, sharing information, and pursuing additional strategies to collect unpaid taxes
Founder: Dr. Mark Pruzanski
VC Investment over the last four quarters: $25 million
Founded in 2002, the 25-employee biopharmaceutical company is in the process of developing therapeutic treatment of chronic fibrotic and metabolic diseases. Despite the downturn, the company raised significant funding this year. Sticking to a tight budget, Intercept expects to have enough cash resources to fund its operations until 2010.
Key to startup success: "Be persistent. Intercept was founded just before the last major downturn for biotech, which lasted through 2003 and venture capital completely dried up for new early-stage startups. [We] remained passionately dedicated to the company and persisted even though it took more than a year to secure financing."